Anika Therapeutics
ANIK
117 hedge funds and large institutions have $300M invested in Anika Therapeutics in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 20 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
24% more capital invested
Capital invested by funds: $242M → $300M (+$58M)
15% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 20
1.8% more ownership
Funds ownership: 88.7% → 90.51% (+1.8%)
2% more funds holding
Funds holding: 115 → 117 (+2)
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
23% less call options, than puts
Call options by funds: $61K | Put options by funds: $79K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Capital Management
Glen Allen,
Virginia
|
+$5.61M |
| 2 |
Morgan Stanley
New York
|
+$4.97M |
| 3 |
AFA
Alta Fundamental Advisers
New York
|
+$3.98M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$2.66M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$5.67M |
| 2 |
Millennium Management
New York
|
-$5.11M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.51M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$2.24M |
| 5 |
TI
Trigran Investments
Northbrook,
Illinois
|
-$1.61M |
ANIK Hedge Fund Activity: Q4 2023 in Review
117 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q4 2023, worth a combined $300M — up 24% from $242M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ANIK positions and 20 closed out — a net gain of 3 holders — while 41 added to existing stakes and 40 trimmed.
The largest buyer was Capital Management, adding an estimated $5.61M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.67M sold.
- 117 institutional investors held Anika Therapeutics (ANIK) as of Q4 2023, up from 115 in Q3 2023.
- Funds reported $300M of Anika Therapeutics stock for Q4 2023, up 24% quarter-over-quarter.
- 23 funds opened new Anika Therapeutics positions in Q4 2023 and 20 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q4 2023 was Capital Management, an estimated $5.61M added.
- The largest Anika Therapeutics seller in Q4 2023 was Janus Henderson Group, an estimated $5.67M sold.
Based on aggregated 13F filings for Q4 2023.